Identification of an m6A RNA Methylation Regulator Risk Score Model for Prediction of Clinical Prognosis in Astrocytoma

Fangzhou Guo, Teng Deng, Liu Shi, Pinghua Wu, Jun Yan, Guoyuan Ling, Hainan Chen, Qianrong Huang, Junbo Mu, and Ligen Mo

Department of Neurosurgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China

Correspondence should be addressed to Ligen Mo; moligen@gxmu.edu.cn

Received 12 November 2021; Revised 5 December 2021; Accepted 9 December 2021; Published 10 January 2022

Academic Editor: Osamah Ibrahim Khalaf

Copyright © 2022 Fangzhou Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Astrocytoma (AS) is the most ubiquitous primary malignancy of the central nervous system (CNS). The vital involvement of the N6-methyladenosine (m6A) RNA modification in the growth of multiple human tumors is known. This study entailed probing m6A regulators with AS prognosis to construct a risk prediction model (RS) for potential clinical use. A total of 579 AS patients’ (of the Chinese Glioma Genome Atlas, CGGA) data and the expression of 12 published m6A-related genes were included in this study. Cox and selection operator (LASSO) regression analyses for independent prognostic factors and multifactor Cox analysis established an RS model to predict the AS patient prognosis. This was subject to verification employing 331 samples from the TCGA data set followed by gene ontology and pathway enrichment study with gene set enrichment analysis (GSEA). The RS constructed with three m6A genes inclusive of WTAP, RBM15, and YTHDF2 emerged as independent prognostic factors in AS patients with vital involvement in the advancement and development of the malignancy. In a nutshell, this work reported an m6A-related gene risk model to predict the prognosis of AS patients to pave the way for discerning diagnostic and prognostic biomarkers. Further corroboration employing relevant wet-lab assays of this model is warranted.

1. Introduction

Astrocytoma (AS) is the most ubiquitous intracranial malignancy, accounting for 40-50% of primary CNS tumors. AS is categorized by the WHO (World Health Organization) as pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, and glioblastoma (grade-I, grade-II, grade-III, and grade-IV, respectively) [1, 2]. Most tumors document a higher recurrence rate post-resection with the occurrence of a higher grade and more aggressive tumor type in the event of relapse. Notwithstanding the extensive use of comprehensive treatment approaches inclusive of surgical resection, radiotherapy, and chemotherapy, the 5-year survival rate of highly aggressive AS is still less than 20%. Another roadblock is the high disability rate after surgery that seriously impacts the patients’ quality of life [3]. In comparison, prognosis prediction and treatment guidance employ traditional clinical risk factors, including tumor grade, preoperative imaging, and IDH gene silencing status. Useful molecular indicators as possible treatment targets have yet to be discovered [4, 5].

The m6A methylation of RNA is modified at the N6-position of the adenine base via methyl transferase catalysis. Currently, this is the most ubiquitous mRNA modification scrutinized in eukaryotic cells and is receiving the center stage in current research [6–8]. The genetic information carried on DNA is first transcribed into mRNA and then further translated into functional proteins. m6A is vitally involved in controlling numerous biological processes, including translation, splicing, nuclear export, and decay of target RNA decay control. The involvement of three types of proteins in m6A methylation has been documented. The first is m6A methyltransferase, which promotes this modification in RNA coded by the "Writer" gene. While METTL3, METTL14, and WTAP were documented earlier, new ones like METTL16 and RBM15 are also emerging [9–11]. The

Hindawi
Computational and Mathematical Methods in Medicine
Volume 2022, Article ID 7168929, 13 pages
https://doi.org/10.1155/2022/7168929
second class of protein is the m6A demethylase that removes the m6A methylation group in RNA. Coded by “Erasers,” examples of these genes include FTO and ALKBH5 [12, 13].

The third type binds with the m6A methylation site in RNA to impact a slew of functions. Their coding genes are termed “Readers.” The gene encoding the YTH domain family proteins (YTHDFs and YTHDCs subtypes) was the earliest documented. This m6A epigenetic modification vitally controls the incidence and progression of malignancies via oncogene or tumor-suppressor gene mRNA molecules to control their expression [14–16]. Yet, the role of m6A in intracranial tumors lacks comprehensive elucidation [17, 18].

Increasing data suggest that N6-methyladenosine (m6A) RNA methylation regulators have a role in carcinogenesis and tumor growth. There is currently no report of a risk model that incorporates m6A regulatory gene mRNA expression levels to investigate AS patients’ prognosis. This study comprehensively analyzed the expression profiles and prognostic value of the m6A RNA methylation regulators risk score model in AS patients through several databases. Finally, the current study systematically confirmed the predictive functions of the m6A RNA methylation regulators risk score model in AS patients.

2. Materials and Methods

2.1. Data Collection. The CGGA (http://www.cgga.org.cn) and the GTEx (http://commonfund.nih.gov/GTEx/) databases were the sources of gene expression and clinical data. This was a total of 579 AS patient data, including 148 patients with astrocytoma (A, WHO grade II), 160 patients with anaplastic astrocytoma (A.A., WHO grade III), and 271 patients with glioblastoma (GBM, WHO grade IV) from the CGGA database. The control encompassed RNA transcriptome datasets of 619 normal human brain tissue specimens from the GTEx database. Standardization of these two database gene expression levels entailed the application of log2 (X + 1) (X is the original expression level of the gene). m6A RNA methylation regulators were selected based on earlier reports and gene expression data as available in the dataset [19–21]. Ultimately, 12 such regulators were included in our scrutiny.

2.2. Differential Expression Analysis of the Regulators. After scrutinizing differentially expressed genes (DEGs) between AS vs. control datasets, the “Limma” package of R software was employed to test the p value, and a violin chart was drawn. Significance was at p < 0.05. Further, m6A regulator interactions were probed by the “Corrplot” and “Spearman” packages in the R software. The regulator expressions were compared by one-way analysis of variance and t-test across different clinical AS datasets with these differences illustrated in heat maps.

2.3. Consensus Clustering of the Regulators. The “Consensus Cluster Plus” package in the R software was employed to probe clusters corresponding to distinct subgroups of the regulators assayed in this work to prove their impact in AS. Following the division of patients into (k = 2 – 9) clusters, the survival analysis on these k clusters was done to scrutinize the survival time variations between groups.

2.4. m6A Regulatory Factor Risk Model Construction. To probe the link between m6A-related genes and prognosis, LASSO [22] and univariate Cox regression analysis were employed in the CGGA gene expression data. The genes demonstrating a significant association with the survival (p < 0.05) were probed to build a risk model (RS) employing the risk model formula below:

\[
RS = \sum_{i=1}^{n} \text{coefi} \times xi
\]

(coefi is the LASSO coefficient of m6A-regulated gene i, and xi is the relative expression of the m6A-regulated gene.)

The R survival package was employed to scrutinize the association in the CGGA database patient set between the 5-year survival rate and the R.S., the risk model (RS). The median value of the R.S. was employed to categorize patients into high-risk and low-risk groups. The Kaplan-Meier (K.M.) plot of the survival curve was constructed at p < 0.05. Further, the receiver operating characteristic (ROC) curve and AUC computation entailed using the survival ROC package to probe the accuracy of the survival analysis.

2.5. Survival Analysis of the m6A RNA Methylation Regulator Risk Model. The utility of the R.S. in AS prognosis was probed employing univariate and multivariate Cox regression analysis using the “survival” and “forest plot” software packages. Comparison of R.S., age, gender, IDH gene status, and tumor grade of the patient set entailed univariate analysis of variance and unpaired t-test. The Kaplan-Meier method and the log-rank test for univariate and multivariate subsistence analysis are independent prognostic factors.

2.6. Risk Model Verification and Biological Function Analysis. The R.S. verification encompassed AS specimen data (n = 331) from the TCGA dataset. The R.S. formula was applied on each sample in this verification set with categorization into high-risk and low-risk groups as outlined above. Apart from the K-M diagram and ROC curve, gene set enrichment analysis employing the GSEA software v4.03 [23] was done to scrutinize the biological processes and pathways of the m6A regulatory factors in the AS in the risk model.

3. Results

3.1. The Pattern of Regulators in AS. The expression of each m6A RNA methylation regulator scrutinized of the malignant vs. control samples is depicted as a heat map (Figure 1(a)). As illustrated, the expression levels of most of these regulators demonstrated an evident correlation with AS incidence (Figure 1(b), p < 0.001), while AS samples showed upregulated METTL3, METTL14, WTAP, RBM15, ZC3H13, HNRNPC, YTHDF1, and YTHDF2 levels.
Figure 1: Continued.
However, opposed to controls, a downregulation of ALKBH5 and FTO also emerged (Figures 1(a) and 1(b)). Subsequent probing of the expression correlation among the 12 m6A regulators to comprehend their interactions (Figure 1(c)). The correlation plot demonstrated a strong coexpression relationship among METTL3, METTL14, WTAP, RBM15, ZC3H13, and HNRNPC. This pattern was also shown in the STRING database (Figure 1(d)).

3.2. Consensus Clustering and Clinical Characteristics of the Regulators in AS. This entailed the incorporation of AS patients with complete clinical information (n = 553) into

Figure 1: m6A RNA methylation regulator expression in AS vs. control brain and samples. (a) Heat maps of regulator expression levels of AS and control samples from CCGA and GTEx databases. (b) Corresponding violin diagrams. (c) Spearman correlation analysis of the thirteen m6A regulators (TCGA database). (d) STRING database (https://string-db.org/) documenting regulator interactions. *p < 0.05, **p < 0.01, and ***p < 0.001; N: normal sample; T: tumor sample.
In the CGGA data set, the clustering stability increased from \( k = 2 \) to \( k = 9 \), with \( k = 3 \) emerging an appropriate choice concerning m6A expression (Figures 2(a)–2(c)). We named them cluster 1, cluster 2, and cluster 3. Subsequently, the clinicopathological features among groups were scored (Figure 3). Evident differences among sets in age, WHO grade of tumors, and IDH gene status emerged \((p < 0.001)\). While cluster 1 was associated with IDH gene mutant, cluster 3 documented an association with advanced age (age 50 years or older) and high-grade tumors.

The median survival times of cluster 1, cluster 2, and cluster 3 emerged as 20.8 months, 18.6 months, and 15.2 months, respectively, with the 5-year survival rate...
documenting no significant difference as per K.M. curves ($p = 0.403$). Therefore, this indicates no association between the survival time and these sample clusters (Figure 2(d)).

3.3. **DEG Selection Related to Prognosis and Risk Model Construction.** From the 10 m6A-related differential genes (DEGs), a total of seven m6A-related DEGs expressive of evidence of the association with the prognosis time arose from the univariate Cox regression analysis ($p < 0.05$). Including the METTL14, WTAP, RBM15, YTHDF1, and YTHDF2 (Figure 4), the Lasso Cox regression analysis ensued to diminish model overfitting (Figures 5(a) and 5(b)). In the end, three genes WTAP, RBM15, and YTHDF2, were chosen for the R.S. model employing the formula below:

$$\text{Risk score} = (0.3428) \times \text{expression level of RBM15} + (0.0803) \times \text{expression level of YTHDF2} + (0.0496) \times \text{expression level of WTAP}.\tag{2}$$

3.4. **Probing the Risk Model in the Training Set.** As elucidated in the materials section, following the categorization of
patients into the risk groups (high and low), clinical characteristics were then scored to probe the predictive value of the three markers mentioned above in AS prognosis (Figure 6(a)). A conspicuous difference emerged for age, WHO grade of tumors, IDH gene mutant status, and tumor type (primary or recurrence) between both groups, with the high-risk group demonstrative of conspicuously elevated expression of the m6A factors assayed as opposed to the low-risk group (Figure 6(a)). The 3-year OS of the former group was 30.3% (95% CI: 25.1%, 36.7%) while that of the low-risk group was 45.1% (95% CI: 39.4%, 51.6%). The 5-year OS rates were 19.6% (95% CI: 14.8%, 26.1%) and 35.5% (95% CI: 29.7%, 42.4%) documenting a statistically significant difference (Figure 5(c), p < 0.01). As outlined in the materials section, the model was probed by the ROC curve with the area under ROC for a 5-year overall survival at 0.716 (Figure 5(d)).

We subsequently probed whether the risk model could be used as a risk factor independent of other clinical features. The WHO tumor stage, IDH gene mutant status, tumor type (whether primary), and the risk score documented a significant relation with the O.S. by the univariate analysis.
Figure 6: Continued.
3.5. Corroboration of the Risk Model. The corroboration of the model entailed the AS patients samples in the TCGA database. After categorizing patients as per the risk, an apparent difference emerged for the 5-year O.S. between the high-risk and the low-risk groups \((p < 0.01)\). The former group (from the target database) was demonstrative of a lower O.S. The AUC of the ROC curve of the model based on the 5-year O.S. was 0.835 (Figure 7(b)). This correlation of the O.S. with the risk model was also demonstrated by univariate regression (Figure 7(c), \(p < 0.01\)). As per the multivariate regression, the risk model emerged as a possible independent predictor of prognosis in AS patients after including the clinical-pathological factors (Figure 7(c), H.R. = 1.193; 95% CI: 1.053–1.352, \(p = 0.002\)). These results are similar to the training set analyses outlining the stability of the constructed risk model.

3.6. Functional Enrichment Analysis. The biological functions and pathways associated with the factors unveiled in this work were scrutinized by GSEA in the CGGA dataset. The high-risk groups demonstrated elevated expression of the biological processes related to tumorigenesis and malignancy progression (Figure 8). These were inclusive of DNA replication (NES = 1.98, \(p < 0.001\)), meiotic cell cycle (NES = 2.00, \(p = 0.002\)), nuclear chromosome segregation (NES = 2.00, \(p < 0.001\)), and STAT receptor signaling pathway (NES = 1.87, \(p = 0.004\)).

4. Discussion

Experimentations and analyses of the m6A modification in malignancies are still in their infancy. Given the diversity and combination of functions, the available literature does not adequately describe regulators’ depth and complexity in this pathway [24, 25]. The more nuanced aspects of functions and molecules are being unveiled by employing high-throughput sequencing and other approaches in this area of science. In terms of clinical application, the scrutiny of whether m6A-related proteins can serve in diagnosis or therapy warrants detailed elucidation.

This work demonstrated the close association of m6A RNA methylation regulator expression and the occurrence and prognosis of AS. Initial regulator expression and consensus cluster analysis probing identified three AS subgroups associated with crucial clinical factors such as IDH status, tumor grade, and age. Besides, we also constructed a risk model with three such regulators and categorized AS patient data into high-risk and low-risk categories employing the risk scores. R.S. model’s efficacy in AS prognosis was demonstrated using both K-M plots and the ROC curve. Its testing corroborated this on patient data from another database (TCGA), unveiling its correctness and applicability.

Current research elucidates the critical role of m6A regulatory factors in carcinogenesis. These variables exhibit distinct regulation pathways across a variety of malignancies. This study discovered the increased expression of three m6A regulatory factors in the high-risk group, namely, RBM15 and WTAP (“readers”), as well as YTHDF2 (a “writer” type).
RBM15 has the most considerable weight in the risk model with its vital involvement in AS progression emerging in this work. The functioning of the human METTL3-METTL14 complex as a 6mA (DNA adenine-N6 MTase) in vitro was unveiled earlier [26]. RBM15 impacts oncogenesis by targeting the METTL3-METTL14 complex [14].

WTAP (Wilms tumor 1 associated protein) was initially identified as a splicing factor interacting with human Wilms tumor one protein [27]. The connection between its overexpression in leukemia and poor prognosis has also been documented. Elevated WTAP augments the proliferation of AML while also inducing delayed differentiation of cells [27]. Similarly, WTAP is overexpressed in cholangiocarcinoma cells, predominantly in lymph nodes or blood vessels, conspicuously augmenting their ability to migrate and invade [28]. Further, drug resistance and the power of several malignancies to proliferate, migrate, and invade are elevated by WTAP to diminish the patient’s O.S. These are inclusive of pancreatic cancer, colorectal cancer, and renal cell carcinoma, to name a few [29–31]. The high expression
of WTAP in GBM and its reasonable correlation with tumor progression have also been documented [32]. Our research on AS is also on these similar lines.

As an m6A reading protein, YTHDF2 can impact the target mRNA expression by recruiting a slew of regulatory or functional systems [33]. YTHDF2 upregulation in prostate cancer tissues to augment the ability of the malignant cells to divide and invade while impacting the tumor suppressor miR-493-3p expression has been corroborated [34]. The YTHDF2 expression was documented to be 83.9% in HCC patient samples with TNM stage III (n = 31). Subsequent assays supported the inhibition of the tumor suppressor gene miR-145 by YTHDF2 via m6A methylation to augment malignant cell proliferation [35]. Only recently has the role of RNA m6A alteration in cancers been discovered. Tumorigenesis is influenced by a myriad of critical biological processes and signaling pathways that have recently been found. Which includes cell cycle control, regeneration of tumor stem cells, DNA damage after radiotherapy, chemotherapy, cellular immune reaction, cellular hypoxia response, miRNA/lncRNA–based aspects, IL-7, STAT5, SOCS pathway, Ca2+–mediated p-ERK12, angiogenesis, enhancer-binding protein alpha signaling pathway, and MMP9, to name a few [36, 37]. Given that m6A is receiving the limelight in studies, our transcription analysis revealed the m6A methylation regulator expression in AS progression. The roadblocks here include the paucity of studies in this sphere that necessitates the

**Figure 8:** The gene set enrichment analysis (GSEA) of the high-risk group.
probing of additional regulators. Further additional data sets are warranted to corroborate the model developed along with appropriate wet-lab assays.

5. Conclusion

The m6A regulatory variables are being investigated in silico to determine their expression status, prognostic significance, and biological roles. A risk model comprising three m6A regulatory genes is being developed as part of this research. The genes identified in this model can be used as new biomarkers for the prognosis of Alzheimer’s disease. In addition, the identification of novel markers may make it easier for the customized prognosis of this malignancy to be incorporated into future therapy approaches. Our findings have revealed the critical role of m6A in AS oncogenesis, potentially paving the road for a cure by targeting this m6A alteration. This research provides a theoretical foundation for further fundamental medical research on m6A and AS.

Data Availability

The data employed to support and corroborate the findings of this work are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Acknowledgments

The authors sincerely thank the researchers for sharing data on the open platform that allowed us to complete this study.

References

[1] D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007.
[2] P. Y. Wen and D. A. Reardon, “Progress in glioma diagnosis, classification and treatment,” Nature Reviews Neurology, vol. 12, no. 2, pp. 69–70, 2016.
[3] W. Yan, S. Fan, J. Feng, D. Xiao, S. Fan, and J. Luo, “Elevated expression of HSP10 protein inhibits apoptosis and associates with poor prognosis of astrocytoma,” PLoS One, vol. 12, no. 10, 2017.
[4] G. Steponaitis, A. Kuzlauskas, D. Skirute, P. Vaitkeiienė, K. Skauminas, and A. Tamasauskas, “Significance of amphiregulin (AREG) for the outcome of low and high grade astrocytoma patients,” Journal of Cancer, vol. 10, no. 6, pp. 1479–1488, 2019.
[5] N. Pecina-Slaus, A. Kalka, K. Gotovac Jerič et al., “Comparative genomic copy number aberrations differ across astrocytoma malignancy grades,” International Journal of Molecular Sciences, vol. 20, no. 5, 2019.
[6] Y. Yue, J. Liu, and C. He, “RNAN6-methyladenosine methylation in post-transcriptional gene expression regulation,” Genes & Development, vol. 29, no. 13, pp. 1343–1355, 2015.
[7] P. Natalia, S. Stephanie, and J. L. W. Justin, “Aberrant expression of enzymes regulating m6A mRNA methylation: implication in cancer,” Cancer Biology & Medicine, vol. 15, no. 4, p. 323, 2018.
[8] T. Sun, R. Wu, and L. Ming, “The role of m6A RNA methylation in cancer,” Biomedicine & Pharmacotherapy, vol. 112, 2019.
[9] Y. Wang, Y. Li, J. I. Toth, M. D. Petroski, Z. Zhang, and J. C. Zhao, “N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells,” Nature Cell Biology, vol. 16, no. 2, pp. 191–198, 2014.
[10] Y. Wang, Y. Li, M. Yue et al., “N6-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications,” Nature Neuroscience, vol. 21, no. 2, pp. 195–206, 2018.
[11] X.-L. Ping, B. F. Sun, L. Wang et al., “Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase,” Cell Research, vol. 24, no. 2, pp. 177–189, 2014.
[12] Y. Huang, J. Yan, Q. Li et al., “Methoclonic acid selectively inhibits FTO demethylation of m6A over ALKBH5,” Nucleic Acids Research, vol. 43, no. 1, pp. 373–384, 2015.
[13] S. Berlijet, J. Scutenaire, J. M. Deragon, and C. Bousquet-Antonelli, “Readers of the m6A epitranscriptomic code,” Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, vol. 1862, no. 3, pp. 329–342, 2019.
[14] D. P. Patil, C. K. Chen, B. F. Pickering et al., “m6A RNA methylation promotes XIST-mediated transcriptional repression,” Nature, vol. 537, no. 7620, pp. 369–373, 2016.
[15] K. D. Meyer and S. R. Jaffrey, “Rethinking m6A readers, writers, and erasers,” Annual Review of Cell and Developmental Biology, vol. 33, no. 1, pp. 319–342, 2017.
[16] X. Wang, Z. Lu, A. Gomez et al., “N6-methyladenosine-dependent regulation of messenger RNA stability,” Nature, vol. 505, no. 7481, pp. 117–120, 2014.
[17] C. Ma, M. Chang, H. Lv et al., “RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum,” Genome Biology, vol. 19, no. 1, pp. 1–18, 2018.
[18] S. Zhang, B. S. Zhao, A. Zhou et al., “m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program,” Cancer Cell, vol. 31, no. 4, pp. 591–606.e6, 2017.
[19] Z. Bi, Y. Liu, Y. Zhao et al., “A dynamic reversible RNA N6-methyladenosine modification: current status and perspectives,” Journal of Cellular Physiology, vol. 234, no. 6, pp. 7948–7956, 2019.
[20] X.-Y. Chen, D. Wang, H. Peng et al., “Epigenetically upregulated oncoprotein PCLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLC–NF-kB signaling pathway and VEGF-C/Bcl-2 expression,” Molecular Cancer, vol. 18, no. 1, pp. 1–9, 2019.
[21] J. Z. Ma, F. Yang, C. C. Zhou et al., “METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulatingN6-methyladenosine-dependent primary MicroRNA processing,” Hepatology, vol. 65, no. 2, pp. 529–543, 2017.
[22] W. Sauerbrei, P. Royston, and H. Binder, “Selection of important variables and determination of functional form for continuous predictors in multivariable model building,” Statistics in Medicine, vol. 26, no. 30, pp. 5512–5528, 2007.
[23] J. Shi and M. G. Walker, “Gene set enrichment analysis (GSEA) for interpreting gene expression profiles,” Current Bioinformatics, vol. 2, no. 2, pp. 133–137, 2007.
[24] D. Han, J. Liu, C. Chen et al., “Author Correction: Antitumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells,” *Nature*, vol. 568, no. 7751, pp. E3–E3, 2019.

[25] M. Cheng, L. Sheng, Q. Gao et al., “The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-xB/MYC signaling network,” *Oncogene*, vol. 38, no. 19, pp. 3667–3680, 2019.

[26] E. Schöller, F. Weichmann, T. Treiber et al., “Interactions, localization, and phosphorylation of the m6A generating METTL3–METTL14–WTAP complex,” *RNA*, vol. 24, no. 4, pp. 499–512, 2018.

[27] N. A. Little, N. D. Hastie, and R. C. Davies, “Identification of WTAP, a novel Wilms’ tumour 1-associating protein,” *Human Molecular Genetics*, vol. 9, no. 15, pp. 2231–2239, 2000.

[28] H.-J. Jo, H. E. Shim, M. E. Han et al., “WTAP regulates migration and invasion of cholangiocarcinoma cells,” *Journal of Gastroenterology*, vol. 48, no. 11, pp. 1271–1282, 2013.

[29] J. Zhang, H. Tsoi, X. Li et al., “Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP–WT1–TBL1 axis,” *Gut*, vol. 65, no. 9, pp. 1482–1493, 2016.

[30] B.-Q. Li, Z. Y. Liang, S. Seery et al., “WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer,” *Cancer Letters*, vol. 451, pp. 48–57, 2019.

[31] J. Tang, F. Wang, G. Cheng et al., “Wilms’ tumour 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability,” *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, pp. 1–12, 2018.

[32] D. I. Jin, S. W. Lee, M. E. Han et al., “Expression and roles of Wilms’ tumour 1-associating protein in glioblastoma,” *Cancer Science*, vol. 103, no. 12, pp. 2102–2109, 2012.

[33] R. Yu, Q. Li, Z. Feng, L. Cai, and Q. Xu, “m6A reader YTHDF2 regulates LPS-induced inflammatory response,” *International Journal of Molecular Sciences*, vol. 20, no. 6, p. 1323, 2019.

[34] J. Li, S. Meng, M. Xu et al., “Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels,” *Oncotarget*, vol. 9, no. 3, pp. 3752–3764, 2018.

[35] Z. Yang, J. Li, G. Feng et al., “MicroRNA-145 modulates N6-methyladenosine levels by targeting the 3’-untranslated mRNA region of the N6-methyladenosine binding YTH domain family 2 protein,” *Journal of Biological Chemistry*, vol. 292, no. 9, pp. 3614–3623, 2017.

[36] S. Liu, Q. Li, K. Chen et al., “The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression,” *Biomedicine & Pharmacotherapy*, vol. 127, 2020.

[37] B. Li, X. Wang, Z. Li et al., “Transcriptome-wide analysis of N6-methyladenosine uncovers its regulatory role in gene expression in the lepidopteran Bombyx mori,” *Insect Molecular Biology*, vol. 28, no. 5, pp. 703–715, 2019.